FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912086695> ?p ?o ?g. }

• W2912086695 endingPage "4079" @default.
• W2912086695 startingPage "4079" @default.
• W2912086695 abstract "Abstract Introduction B cell acute lymphoblastic leukemia (B-ALL) is a severe disease caused by malignant transformation and uncontrolled proliferation of immature B lymphocytes. Blinatumomab, a Bi-specific T cell engager (BiTE®) combining the VH and VL domains of two antibodies against human CD19 and CD3, has been approved by U.S. Food and Drug Administration (FDA) for the treatment of Philadelphia chromosome negative (Ph-) relapsed or refractory B-ALL in 2014, and recently Philadelphia chromosome-positive (Ph+) B-ALL. Blinatumomab brings killer T and target B cells into close proximity, activating patients' autologous T cells to kill both normal and malignant B cells via mechanisms such as cytolytic immune synapse formation and inflammatory cytokine production. Clinical trials have shown that there are still patients refractory to blinatumomab. It is thus of great importance to understand the resistance mechanisms and search for biomarkers for patient selection. Methods and Results In this study, we used Mass cytometry-based immunophenotyping and Luminex based multiple protein quantitation, to search for biomarkers correlated with the killing capacity of blinatumomab. First, we collected PBMCs from 12 B-ALL patients for an in vitro killing assay, focusing on the quantity and quality profiling of T cells. PBMCs were used as the effector cells and NALM-6 as the target cells. The final effector to target (E/T) ratio is 10:1. Blinatumomab were added to the co-cultured cells (final concentration 10 ng/mL) for 18hrs. A 5% specific lysis of NALM-6 was used as cut-off threshold. Samples with specific killing above 5% were classified as positive for blinatumomab response, and below 5% as negative. Among the patients analyzed, 4 out of 12 patients (33.3%) showed apparent and specific lysis of NALM6 leukemia cells, while the remaining samples showed no obvious effect. This divergent killing effect of blinatumomab with the presence of PBMCs from different donors may reflect the differentiated treatment response in B-ALL patients. Concurrently we immunophenotyped each patient's PBMCs by Mass cytometry with a panel of antibodies for surface lineage markers and intracellular effector molecules and cytokines /chemokines. Unsupervised clustering showed that a panel of T-cell associated biomarkers highly significantly correlated with B-ALL cell response to blinatumomab (p=0.001, R=0.839). This panel of biomarkers included T cell markers of CD45, CD3 and CD4; cytolytic proteins of Perforin and GranzymeB; cytokines of IL-2, INFγ and TNFα; and chemokine CCL4 (also known as MIP-1b). In a Luminex analysis examining multiple proteins accumulating in the culture supernatant from the in vitro killing assay, the top biomarkers identified by Mass cytometry also showed significant response to blinatumomab at different time points (12, 24 and 48 hrs). They included TNF-α, CCL4, IL-2, INFγ and Granzyme B. Furthermore, released CCL4 at 24 and 48 hrs and INFγ at 48 hrs significantly correlated with blinatumomab mediated cytotoxicity. Conclusion In summary, the immunophenotyping and multiplexed protein measurement by Mass cytometry and Luminex assay identified key biomarkers that may correlate with blinatumomab-mediated killing of B-ALL leukemia cells. The biomarker panel reflected the importance of primed T cell activation, associated key cytokine/chemokine as well as the consequent cytolytic protein release in the overall response to blinatumomab. Thus, in vitro biomarker profiling focusing on T cell status with these key molecules may facilitate patient selection and predict the response to the immunotherapy. Disclosures Fu: Amgen: Research Funding." @default.
• W2912086695 created "2019-02-21" @default.
• W2912086695 creator A5017077218 @default.
• W2912086695 creator A5033207412 @default.
• W2912086695 creator A5036845679 @default.
• W2912086695 creator A5037031981 @default.
• W2912086695 creator A5045069173 @default.
• W2912086695 creator A5047692322 @default.
• W2912086695 creator A5052883326 @default.
• W2912086695 creator A5060803217 @default.
• W2912086695 creator A5062207689 @default.
• W2912086695 creator A5068538895 @default.
• W2912086695 creator A5073976864 @default.
• W2912086695 creator A5074757286 @default.
• W2912086695 creator A5076306729 @default.
• W2912086695 creator A5078362508 @default.
• W2912086695 creator A5083766150 @default.
• W2912086695 date "2018-11-29" @default.
• W2912086695 modified "2023-10-12" @default.
• W2912086695 title "Patient's T Cell Functionality Determines Blinatumomab-Mediated Killing of B-ALL Leukemia Cells" @default.
• W2912086695 doi "https://doi.org/10.1182/blood-2018-99-114503" @default.
• W2912086695 hasPublicationYear "2018" @default.
• W2912086695 type Work @default.
• W2912086695 sameAs 2912086695 @default.
• W2912086695 citedByCount "0" @default.
• W2912086695 crossrefType "journal-article" @default.
• W2912086695 hasAuthorship W2912086695A5017077218 @default.
• W2912086695 hasAuthorship W2912086695A5033207412 @default.
• W2912086695 hasAuthorship W2912086695A5036845679 @default.
• W2912086695 hasAuthorship W2912086695A5037031981 @default.
• W2912086695 hasAuthorship W2912086695A5045069173 @default.
• W2912086695 hasAuthorship W2912086695A5047692322 @default.
• W2912086695 hasAuthorship W2912086695A5052883326 @default.
• W2912086695 hasAuthorship W2912086695A5060803217 @default.
• W2912086695 hasAuthorship W2912086695A5062207689 @default.
• W2912086695 hasAuthorship W2912086695A5068538895 @default.
• W2912086695 hasAuthorship W2912086695A5073976864 @default.
• W2912086695 hasAuthorship W2912086695A5074757286 @default.
• W2912086695 hasAuthorship W2912086695A5076306729 @default.
• W2912086695 hasAuthorship W2912086695A5078362508 @default.
• W2912086695 hasAuthorship W2912086695A5083766150 @default.
• W2912086695 hasBestOaLocation W29120866951 @default.
• W2912086695 hasConcept C153911025 @default.
• W2912086695 hasConcept C154317977 @default.
• W2912086695 hasConcept C159654299 @default.
• W2912086695 hasConcept C196166836 @default.
• W2912086695 hasConcept C202751555 @default.
• W2912086695 hasConcept C203014093 @default.
• W2912086695 hasConcept C2776090121 @default.
• W2912086695 hasConcept C2778020697 @default.
• W2912086695 hasConcept C2778453870 @default.
• W2912086695 hasConcept C2778957590 @default.
• W2912086695 hasConcept C502942594 @default.
• W2912086695 hasConcept C553184892 @default.
• W2912086695 hasConcept C55493867 @default.
• W2912086695 hasConcept C71924100 @default.
• W2912086695 hasConcept C86803240 @default.
• W2912086695 hasConcept C8891405 @default.
• W2912086695 hasConceptScore W2912086695C153911025 @default.
• W2912086695 hasConceptScore W2912086695C154317977 @default.
• W2912086695 hasConceptScore W2912086695C159654299 @default.
• W2912086695 hasConceptScore W2912086695C196166836 @default.
• W2912086695 hasConceptScore W2912086695C202751555 @default.
• W2912086695 hasConceptScore W2912086695C203014093 @default.
• W2912086695 hasConceptScore W2912086695C2776090121 @default.
• W2912086695 hasConceptScore W2912086695C2778020697 @default.
• W2912086695 hasConceptScore W2912086695C2778453870 @default.
• W2912086695 hasConceptScore W2912086695C2778957590 @default.
• W2912086695 hasConceptScore W2912086695C502942594 @default.
• W2912086695 hasConceptScore W2912086695C553184892 @default.
• W2912086695 hasConceptScore W2912086695C55493867 @default.
• W2912086695 hasConceptScore W2912086695C71924100 @default.
• W2912086695 hasConceptScore W2912086695C86803240 @default.
• W2912086695 hasConceptScore W2912086695C8891405 @default.
• W2912086695 hasIssue "Supplement 1" @default.
• W2912086695 hasLocation W29120866951 @default.
• W2912086695 hasOpenAccess W2912086695 @default.
• W2912086695 hasPrimaryLocation W29120866951 @default.
• W2912086695 hasRelatedWork W1991837516 @default.
• W2912086695 hasRelatedWork W2891679914 @default.
• W2912086695 hasRelatedWork W2908839165 @default.
• W2912086695 hasRelatedWork W2912086695 @default.
• W2912086695 hasRelatedWork W2953331326 @default.
• W2912086695 hasRelatedWork W2953853904 @default.
• W2912086695 hasRelatedWork W3081598929 @default.
• W2912086695 hasRelatedWork W3145562791 @default.
• W2912086695 hasRelatedWork W3180719608 @default.
• W2912086695 hasRelatedWork W3184498267 @default.
• W2912086695 hasVolume "132" @default.
• W2912086695 isParatext "false" @default.
• W2912086695 isRetracted "false" @default.
• W2912086695 magId "2912086695" @default.
• W2912086695 workType "article" @default.